To reiterate, anti-PD-1 in the context of PD1-IL2v is used to deliver the bispecific molecule to tumors and is not supplied at a sufficient saturating dose to fully block PD-1 checkpoint activity. We chose to utilize PD-L1 antibody treatment instead of high-dose anti-PD-1 to circumvent...
[19]. For example, in lung cancer, terminally exhausted T cells expressing HPK1+PD1+TIM-3+CD8+are associated with poor prognosis [20], while glioblastoma studies suggest a link between low CD8+CD103+PD1+TIM3+Trm cells and prolonged survival [21]. Such heterogeneity limits the utility of ...